Voiant, a Waltham, MA-based scientific trial imaging options supplier, acquired Voxeleron, an Austin, TX-based firm which specializes AI-driven ophthalmic picture evaluation.
The quantity of the deal was not disclosed.
With the acquisition, Volant will speed up the event of revolutionary therapies for eye ailments.
Voxeleron is an AI-driven ophthalmic picture evaluation firm providing superior options for purposes in medication, biology, and past. Its platform gives picture evaluation software program for all ophthalmic imagery, enabling researchers to speed up scientific analysis, generate actionable outcomes, and drive higher affected person outcomes.
Led by CEO Jim Primerano, Voiant is an AI-based scientific trial imaging answer supplier with scientific and scientific area experience, providing biopharmaceutical corporations with high-speed supply of high quality scientific endpoint information.
The corporate will leverage its newly mixed capabilities with continued funding to advance biomarker growth and picture evaluation capabilitie
FinSMEs
18/04/2025
